Why Alzheimer's is a disease of memory: The attack on synapses by Aβ oligomers (ADDLs)

Journal of Nutrition, Health and Aging

Volumn 12, Issue 1, 2008, Pages

  Viola, K L ^a   Velasco, P T ^a   Klein, W L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; OLIGOMER; SYNAPSE RECEPTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ARC GENE; BRAIN; CLINICAL FEATURE; CONFERENCE PAPER; CYTOLOGY; DISEASE MODEL; GENE; GENE OVEREXPRESSION; MEMORY; MEMORY DISORDER; MORPHOLOGY; NEUROPATHOLOGY; NONHUMAN; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SPINE; SYNAPSE;

MUS;

EID: 38549152764     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Lambert,M.P., Barlow,A.K., Chromy,B.A., Edwards,C., Freed,R., Liosatos,M., Morgan,T.E., Rozovsky,I., Trommer,B., Viola,K.L., Wals,P., Zhang,C., Finch,C.E., Krafft,G.A. & Klein,W.L. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A 95, 6448-6453.
2. Gong,Y., Chang,L., Viola,K.L., Lacor,P.N., Lambert,M.P., Finch,C.E., Krafft,G.A. & Klein,W.L. (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A 100, 10417-10422.
3. Ishibashi,K., Tomiyama,T., Nishitsuji,K., Hara,M. & Mori,H. (2006) Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain. J Neurosci. Res. 84, 632-636.
4. Lesne,S., Koh,M.T., Kotilinek,L., Kayed,R., Glabe,C.G., Yang,A., Gallagher,M. & Ashe,K.H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
5. Lacor,P.N., Buniel,M.C., Chang,L., Fernandez,S.J., Gong,Y., Viola,K.L., Lambert,M.P., Velasco,P.T., Bigio,E.H., Finch,C.E., Krafft,G.A. & Klein,W.L. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 24, 10191-10200.
6. De Felice,F.G., Velasco,P.T., Lambert,M.P., Viola,K., Fernandez,S.J., Ferreira,S.T. & Klein,W.L. (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 282, 11590-11601.
7. Lacor,P.N., Buniel,M.C., Furlow,P.W., Clemente,A.S., Velasco,P.T., Wood,M., Viola,K.L. & Klein,W.L. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 27, 796-807.
8. Hardy,J. & Selkoe,D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
9. Selkoe,D.J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
10. El Agnaf,O.M., Walsh,D.M. & Allsop,D. (2003) Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol. 2, 461-462.
11. Caughey,B. & Lansbury,P.T., Jr. (2003) Protofibrils, Pores, Fibrils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders. Annu. Rev. Neurosci. 26, 267-298.
12. Mattson,M.P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639.
13. Walsh,D.M. & Selkoe,D.J. (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193.
14. Walsh,D.M., Klyubin,I., Shankar,G.M., Townsend,M., Fadeeva,J.V., Betts,V., Podlisny,M.B., Cleary,J.P., Ashe,K.H., Rowan,M.J. & Selkoe,D.J. (2005) The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 33, 1087-1090.
15. Rowan,M.J., Klyubin,I., Wang,Q. & Anwyl,R. (2005) Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem. Soc. Trans. 33, 563-567.
16. Glabe,C.G. (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570-575.
17. Standridge, J.B. (2006) Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. Curr. Alzheimer Res. 3, 95-108.
18. Klein,W.L., Lacor,P.N., De Felice,F.G. & Ferreira,S.T. Molecules that disrupt memory circuits in Alzheimer's disease: the attack on synapses by Abeta oligomers (ADDLs). In Memories: Molecules and Circuits. Bontempi,B., Silva,A.J. & Christen,Y. (eds.), pp. 155-179 (Springer, New York,2006).
19. Smith,A. (2003) Amyloid-?: less bark, more bite! Nat. Rev. Drug Discov. 2, 771.
20. Valeo,T. (2004) Downsized target. Sci. Am. 290, 26, 28.
21. Keating,C.D. (2005) Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc. Natl. Acad. Sci. U. S. A 102, 2263-2264.
22. Fradinger,E.A. & Bitan,G. (2005) En route to early diagnosis of Alzheimer's disease - are we there yet? Trends Biotechnol. 23, 531-533.
23. Hardy,J.A. & Higgins,G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
24. Dodart,J.C., Bales,K.R., Gannon,K.S., Greene,S.J., DeMattos,R.B., Mathis,C., DeLong,C.A., Wu,S., Wu,X., Holtzman,D.M. & Paul,S.M. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 5, 452-457.
25. Kotilinek,L.A., Bacskai,B., Westerman,M., Kawarabayashi,T., Younkin,L., Hyman,B.T., Younkin,S. & Ashe,K.H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335.
26. Frackowiak,J., Zoltowska,A. & Wisniewski,H.M. (1994) Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J. Neuropathol. Exp. Neurol. 53, 637-645.
27. Kuo,Y.M., Emmerling,M.R., Vigo-Pelfrey,C., Kasunic,T.C., Kirkpatrick,J.B., Murdoch,G.H., Ball,M.J. & Roher,A.E. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081.
28. Chromy,B.A., Nowak,R.J., Lambert,M.P., Viola,K.L., Chang,L., Velasco,P.T., Jones,B.W., Fernandez,S.J., Lacor,P.N., Horowitz,P., Finch,C.E., Krafft,G.A. & Klein,W.L. (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 12749-12760.
29. Boutaud,O., Montine,T.J., Chang,L., Klein,W.L. & Oates,J.A. (2006) PGH-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem. 96, 917-923.
30. Wang,H.W., Pasternak,J.F., Kuo,H., Ristic,H., Lambert,M.P., Chromy,B., Viola,K.L., Klein,W.L., Stine,W.B., Krafft,G.A. & Trommer,B.L. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140.
31. Cleary,J.P., Walsh,D.M., Hofmeister,J.J., Shankar,G.M., Kuskowski,M.A., Selkoe,D.J. & Ashe,K.H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84.
32. Lambert,M.P., Viola,K.L., Chromy,B.A., Chang,L., Morgan,T.E., Yu,J., Venton,D.L., Krafft,G.A., Finch,C.E. & Klein,W.L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595-605.
33. Lambert,M.P., Velasco,P.T., Chang,L., Viola,K.L., Fernandez,S., Lacor,P.N., Khuon,J.J., Gong,Y., Bigio,E.H., Shaw,P., De Felice,F.G., Krafft,G.A. & Klein,W.L. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 100, 23-35.
34. Kayed,R., Head,E., Thompson.J.L., McIntire,T.M., Milton,S.C., Cotman,C.W. & Glabe,C.G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
35. Chang,L., Bakhos,L., Wang,Z., Venton,D.L. & Klein,W.L. (2003) Femtomole immunodetection of synthetic and endogenous Amyloid-? oligomers and its application to Alzheimer's Disease drug candidate screening. J. Mol. Neurosci. 20, 305-313.
36. Georganopoulou,D.G., Chang,L., Nam,J.M., Thaxton,C.S., Mufson,E.J., Klein,W.L. & Mirkin,C.A. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 102, 2273-2276.
37. Schneider,A., Schulz-Schaeffer,W., Hartmann,T., Schulz,J.B. & Simons,M. (2006) Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol. Dis. 23, 573-577.
38. Townsend,M., Shankar,G.M., Mehta,T., Walsh,D.M. & Selkoe,D.J. (2006) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572, 477-492.
39. Kokubo,H., Kayed,R., Glabe,C.G. & Yamaguchi,H. (2005) Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res. 1031, 222-228.
40. Zhao,W.Q., De Felice,F.G., Fernandez,S., Chen,H., Lambert,M.P., Quon,M., Krafft,G.A. & Klein,W.L. (2007) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J .
41. Guzowski,J.F., Lyford,G.L., Stevenson,G.D., Houston,F.P., McGaugh,J.L., Worley,P.F. & Barnes,C.A. (2000) Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J. Neurosci. 20, 3993-4001.
42. Guzowski,J.F. (2002) Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches. Hippocampus 12, 86-104.
43. Kaufmann,W.E. & Moser,H.W. (2000) Dendritic anomalies in disorders associated with mental retardation. Cereb. Cortex 10, 981-991.
44. Halpain,S., Spencer,K. & Graber,S. (2005) Dynamics and pathology of dendritic spines. Prog. Brain Res. 147, 29-37.
45. Zhao,W.Q. & Alkon,D.L. (2001) Role of insulin and insulin receptor in learning and memory. Mol. Cell Endocrinol. 177, 125-134.
46. Ferrer,I., Boada,R.M., Sanchez Guerra,M.L., Rey,M.J. & Costa-Jussa,F. (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14, 11-20.
47. De Felice,F.G., Vieira,M.N., Saraiva,L.M., Figueroa-Villar,J.D., Garcia-Abreu,J., Liu,R., Chang,L., Klein,W.L. & Ferreira,S.T. (2004) Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J 18, 1366-1372.
48. Wang,Z., Chang,L., Klein,W.L., Thatcher,G.R. & Venton,D.L. (2004) Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med. Chem. 47, 3329-3333.
49. Walsh,D.M., Townsend,M., Podlisny,M.B., Shankar,G.M., Fadeeva,J.V., Agnaf,O.E., Hartley,D.M. & Selkoe,D.J. (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci. 25, 2455-2462.
50. Wu,Y., Wu,Z., Butko,P., Christen,Y., Lambert,M.P., Klein,W.L., Link,C.D. & Luo,Y. (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 26, 13102-13113.
51. Witt,A., Macdonald,N. & Kirkpatrick,P. (2004) Memantine hydrochloride. Nat. Rev. Drug Discov. 3, 109-110